About Us

Our Leadership Team

• 

  Weimin Wang, Ph.D.

  Founder, Chief Executive Officer

  Dr. Weimin Wang is a pioneer in the field of oligonucleotide medicinal chemistry with nearly 30 years of experience in the RNA therapeutics industry. He held scientific leadership positions at Sirna Therapeutics (one of the first RNAi biotech companies, acquired by Merck in 2006), Merck & Co., and Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2022). Dr. Weimin Wang was a key contributor of innovative RNAi delivery solutions including GalXC™ and GalXC-Plus™ technologies. He contributed to the development of multiple impactful RNAi medicines such as Rivfloza® for primary hyperoxaluria, Xalnesiran for chronic HBV infection, and Lepodisiran for cardiovascular disease.

  Dr. Wang holds a Ph.D. in organic chemistry from Rutgers, The State University of New Jersey and an M.S. in physical chemistry and a B.S. in chemistry from Peking University. He has authored over 70 scientific papers and patents in the field.

• 

  Shiyu Wang, Ph.D.

  Co-Founder, Chief Scientific Officer

  Dr. Shiyu Wang has over 17 years of research experience in siRNA and antisense oligonucleotides therapeutic development. She brings extensive industry experience in the molecular mechanism of oligonucleotide delivery, disease-causing genes identification, lead optimization, in vitro and in vivo pharmacology, assay development, and hepatic and extrahepatic delivery platform discovery. During her tenure in scientific leadership roles at Ionis Pharmaceuticals and Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2022), she spearheaded numerous key preclinical studies using various disease models, led multidisciplinary teams advancing internal and external programs from target identification through late-stage development. She also managed strategic collaborations with leading pharmaceutical companies, including Eli Lilly and Novo Nordisk.

  Dr. Wang holds a Ph.D. in molecular biology from The Pennsylvania State University, and an M.S. in biotechnology and chemistry and a B.S. in biology from Jilin University.

  
  

  
  

• 

  Marc Abrams, Ph.D.

  Chief Technology Officer, Head of US Operations

  Dr. Marc Abrams has nearly 30 years of leadership experience in oligonucleotide therapeutics and targeted delivery of genetic medicines. Prior to joining SanegeneBio, he spent over 16 years at Merck & Co., where he held roles of increasing responsibility in small molecule and nucleic acid drug discovery and development. He later served as Senior Vice President of Discovery Research at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2022), and as Chief Scientific Officer at Carbon Biosciences, where he led multiple major RNAi drug discovery and development programs. Dr. Abrams also served on SanegeneBio's Scientific Advisory Board.

  Dr. Marc Abrams holds a Ph.D. in biochemistry from Thomas Jefferson University, an M.S. in biology in biology from University of Rochester and a B.S. from Drexel University.

  
  

  
  

• 

  Yuyan Jin, Ph.D.

  Chief Development Officer

  Dr. Yuyan Jin has over 17 years of experience in global pharmaceutical research and development. Prior to joining SanegeneBio, she held multiple leadership positions at Pfizer U.S. headquarters and the Roche China Innovation Center, where she has led and engaged in preclinical research, early clinical development, and regulatory submissions for multiple innovative programs across neuroscience, oncology, infection, and immunology diseases. She also served as a Critical Path Research Fellow at the U.S. Food and Drug Administration (FDA) for two years, where she contributed to public health models supporting the optimal use of antihypertensive therapeutics. As a member of scientific expert committees in China, Dr. Jin has also contributed to the development of multiple technical guidance documents.

  Dr. Jin holds a Ph.D. in Clinical Pharmacology from the University of Pittsburgh and completed the one-year global Clinical Scholars Research Training program at Harvard Medical School.

  
  

• 

  Jennifer Lockridge, Ph.D.

  Executive Product Development Advisor

  Dr. Jennifer Lockridge brings 30 years of leadership and expertise in developing RNAi and other oligonucleotide therapeutics. For the past decade, she served as SVP/VP, Program Development at Dicerna Pharmaceuticals and its post-acquisition successor organization, Global Nucleic Acid Therapies at Novo Nordisk. Her teams have been responsible for nonclinical and early clinical studies and regulatory submissions worldwide, including leading many aspects of the development of Rivfloza® (Nedosiran), an approved RNAi medicine for primary hyperoxaluria. She also recently served in an Expert Working Group for the drafting of ICH S13 Guidance for Nonclinical Safety Studies of Oligonucleotide-Based Therapeutics. 

  Dr. Lockridge holds a Ph.D. in Pharmacology from Oregon Health Sciences University (now Oregon Health & Science University). 

  
  

• 

  Yang Liu, MBA

  Senior Vice President of Business Development

  Mr. Yang Liu has over 15 years of strategy and business development experiences in the pharmaceutical industry. He has successfully led or engaged in various types of transactions at different stages and across different therapeutic areas, including nearly 20 collaborations such as strategic investment, M&A, licensing in/out, co-development, and funded research, with increasing responsibilities at Pfizer, Shire, Boehringer Ingelheim and Roche.

  Mr. Yang Liu holds an MBA from Antai College of Economics and Management, Shanghai Jiao Tong University, an M.S. in Cell Biology and a B.S. from University of Science and Technology of China.

  
  

• 

  Sibo Jiang, Ph.D.

  Vice President of CMC

  Dr. Sibo Jiang has over 15 years of experience in oligonucleotide synthesis and CMC development, with deep expertise in process and analytical development, method optimization, process validation, raw material control, and GLP/GMP scale-up manufacturing. Prior to joining SanegeneBio, Dr. Jiang has held several positions with increasing responsibility at the global leading oligonucleotide CDMO Nitto Denko Avecia. Under his leadership, the oligonucleotide team had completed 70+ development and production projects, advancing oligonucleotide programs from preclinical through commercial phases.

  Dr.Sibo Jiang holds a Ph.D. in Organic Chemistry from Georgia State University and a B.S. in Polymer Chemistry from Jilin University.

  
  

• 

  Wei Ren Campbell, J.D.

  Vice President of Intellectual Property

  Wei R. Campbell is an intellectual property attorney with 15 years of experience on a broad range of IP matters in biotechnology, pharmaceuticals, and life sciences, including patent strategy, global patent portfolio development and management, due diligence, IP litigation, transactional matters, trademarks, copyrights, trade secrets, and client counseling. Prior to joining SanegeneBio, she held important positions at biopharmaceutical companies such as Alnylam and BeiGene, leading the development of comprehensive global patent portfolios including oligonucleotide therapies and small molecule drugs, and optimizing global market exclusivity for commercial assets and pipeline programs.

  Dr.Ren holds a J.D. from New England School Law | Boston, an M.S. in Medical Nutrition Sciences from Boston University School of Medicine and a B.S. from Peking University Health Science Center.

  
  

• 

  Na Meng, CFA

  Vice President of Capital Markets

  Ms. Na Meng has over a decade of experience in strategy and capital markets within the healthcare sector. She started her career at Bank of America Merrill Lynch and Deutsche Bank in Hong Kong, covering the Asia-Pacific healthcare sector. She has since led corporate strategy, capital markets, and investor relations at I-Mab and Genorbio, where she successfully executed a number of landmark transactions including IPOs, spin-offs, and strategic partnerships. 

  Ms. Meng earned an M.S. in Management from HEC Paris and a B.S. from Fudan University, and is a Chartered Financial Analyst.

  
  

• 

  Pancheng Chen

  Vice President of Legal Affairs

  Pancheng (Pan) Chen has over 10 years of experience advising life science and technology companies and their investors on complex corporate and strategic transactions, including venture capital financings, mergers and acquisitions, joint ventures, and cross-border strategic collaborations. At SanegeneBio, he is responsible for the Company's legal strategy, corporate governance and transactional matters. Prior to joining SanegeneBio, Pan practiced at Sidley Austin LLP and Cooley LLP, two of the world's leading international law firms, and served as the Company's outside legal counsel from its inception, advising SanegeneBio through every round of financing and each major milestone transaction in its development. 
  
  Pan holds an LL.M. from the University of California, Berkeley School of Law, and an LL.M. and LL.B. from East China University of Political Science and Law.